Hello and welcome to Intelligence Squared, where great minds meet.
I'm Dr.
Ganesh Taylor, a fellow and group leader at the University of Edinburgh.
This episode is part of the Prostate Cancer Perspective series,
brought to you in collaboration with Bayer.
Today we'll be tackling the future of prostate cancer care,
reflecting on what prostate cancer care means in practice and how the way we think about the disease is shifting and must continue to shift in the years ahead.
Prostate cancer is the second most common cancer in men and the fifth leading cause of cancer death worldwide.
Each year around 1.5 million men are diagnosed and nearly 400,000 lose their lives to the disease.
And these numbers are rising.
Diagnoses are in fact projected to double from 1.4 million annually in 2020 to 2.9 million by 2040.
In the US,
the proportion of men diagnosed with advanced-stage prostate cancer has doubled in recent years.
This is due to the increasing incidence of advanced stage disease and changing guidelines regarding the prostate-specific antigen screening test implemented in the US in 2012.
In England, nearly one in five men are diagnosed only once the cancer has already spread.
Scientific advances have transformed treatment in recent years,
yet the lived reality of prostate cancer still extends far beyond the clinic.
The disease reshapes daily life and may leave men and their families grappling with difficult choices about how to manage the disease.
Advanced prostate cancer is often associated with long-term challenges leading to greater levels of unmet needs in supportive care.
In today's discussion,